ecNOS overexpression in CsA-treated renal transplant patients: implications for CsA-induced hypertension.
Calò
L
L
Institute of Internal Medicine, University of Padua, Italy.
Davis
P A
PA
Rigotti
P
P
Milani
M
M
Cantaro
S
S
Marchini
F
F
D'Angelo
A
A
Antonello
A
A
D016572:Cyclosporine / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000503:physiopathology; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D009000:Monocytes / Q000201:enzymology; D009569:Nitric Oxide / Q000097:blood; D019001:Nitric Oxide Synthase / Q000096:biosynthesis* / Q000235:genetics; D052250:Nitric Oxide Synthase Type III; D016133:Polymerase Chain Reaction / Q000379:methods; D012333:RNA, Messenger / Q000097:blood; D012016:Reference Values
D007166:Immunosuppressive Agents; D012333:RNA, Messenger; D009569:Nitric Oxide; D016572:Cyclosporine; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III